8-K Announcements
6Material company update
Nov 19, 2025·SEC
Material company update
Nov 12, 2025·SEC
Material company update
Aug 8, 2025·SEC
Surmodics, Inc.(SRDX)Earnings, Financials & Key Ratios
SRDX•NASDAQ
$42.98
Price updated Jun 20, 2026
AboutSurmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Show more
- Revenue$126M-4.9%
- EBITDA$3M-78.7%
- Net Income-$12M-651.4%
- EPS (Diluted)-0.82-645.5%
- Gross Margin73.81%+60.4%
- EBITDA Margin2.42%-77.6%
- Operating Margin-4.48%-215.3%
- Net Margin-9.15%-690.2%
- ROE-9.67%-618.4%
SRDX Price & Volume
Surmodics, Inc. (SRDX) stock price & volume — 10-year historical chart
Loading chart...
Strategic Pivot Pressures Margins and Liquidity
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Mixed
Primary Risk:Commercialization and Scale Execution
Key Thesis Takeaways
- Surmodics is currently navigating a challenging transition from a high-margin licensing model to a direct-market interventional device manufacturer, which has resulted in persistent operating losses and revenue contraction.
- While the company maintains a relatively stable debt-to-equity ratio of 0.29, the inability to achieve operating leverage—evidenced by a -17.7% operating margin in 2025Q3—raises significant concerns regarding the scalability of its new product portfolio.
- Investors should monitor the company's ability to stabilize its cash position, which has declined to $26.3 million, against the backdrop of intense competition in the peripheral vascular device market.
Verdict Logic
the company's inability to generate consistent free cash flow, evidenced by the volatility between a $25.4 million peak in 2023Q3 and a -$9.5 million trough in 2024Q1, suggests significant execution risk during its commercialization phase.
SRDX Growth Metrics
Surmodics, Inc. (SRDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.18%
5 Years4.73%
3 Years6.24%
TTM-0.02%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1159.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1151.27%
Return on Capital
10 Years2.68%
5 Years-2.35%
3 Years-5.05%
Last Year-3.53%
SRDX Recent Earnings
Surmodics, Inc. (SRDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q3 2025Latest
Aug 8, 2025Metric
Actual
Est
EPS
$0.06+128.6%
$0.21
Rev
$30M-1.4%
$30M
Q2 2025
Apr 30, 2025Metric
Actual
Est
EPS
$0.13-116.7%
$0.06
Rev
$28M-12.9%
$32M
Q1 2025
Jan 30, 2025Metric
Actual
Est
EPS
$0.04+66.7%
$0.12
Rev
$30M-10.3%
$33M
Q4 2024
Nov 6, 2024Metric
Actual
Est
EPS
$0.13+51.9%
$0.27
Rev
$33M+9.3%
$30M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2025Latest | Aug 8, 2025 | $0.06vs $0.21+128.6% | $30Mvs $30M-1.4% |
| Q2 2025 | Apr 30, 2025 | $0.13vs $0.06-116.7% | $28Mvs $32M-12.9% |
| Q1 2025 | Jan 30, 2025 | $0.04vs $0.12+66.7% | $30Mvs $33M-10.3% |
| Q4 2024 | Nov 6, 2024 | $0.13vs $0.27+51.9% | $33Mvs $30M+9.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Surmodics, Inc. (SRDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.98 | $614.51M | -52.41 | -4.91% | -9.15% | -9.67% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $32.39 | $1.64B | -134.96 | 14.88% | -0.83% | -0.95% | — | |
| $12.98 | $536.32M | -15.64 | -3.76% | -10% | -17.65% | — | |
| $12.13 | $119.71M | -4.61 | 15.21% | -10.88% | -15.54% | — | |
| $71.45 | $4.26B | 33.54 | 11.66% | 9.03% | 8.95% | — |
Compare SRDX vs Peers
Surmodics, Inc. (SRDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRDX SEC Filings & Documents
Surmodics, Inc. (SRDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SRDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRDX Frequently Asked Questions
Surmodics, Inc. (SRDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Surmodics, Inc.'s revenue?
Surmodics, Inc. (SRDX) reported $120.8M in revenue for fiscal year 2024. This represents a 1133% increase from $9.8M in 1998.
How fast is Surmodics, Inc. growing?
Surmodics, Inc. (SRDX) saw revenue decline by 4.9% over the past year.
Is SRDX profitable?
Surmodics, Inc. (SRDX) reported a net loss of $17.6M for fiscal year 2024.
Dividend & Returns
What is SRDX's return on equity?
Surmodics, Inc. (SRDX) has a return on equity (ROE) of -9.7%. Negative ROE indicates the company is unprofitable.
What is Surmodics, Inc.'s free cash flow?
Surmodics, Inc. (SRDX) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.